# Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Source: https://onco.cc/trials/nct05607953/  
OnCo record `nct05607953` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Nelitolimod run by TriSalus Life Sciences, Inc., active, not recruiting.

## Summary

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma is a phase 1 interventional study registered as NCT05607953 by TriSalus Life Sciences, Inc., with 60 participants planned, started 2023-03-01, primary completion expected 2027-09. Conditions recorded: Locally Advanced Pancreatic Adenocarcinoma. Interventions recorded: SD-101, anti-PD-1.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05607953
- Phase: 1
- Setting: A Phase 1/1b Pressure Enabled Regional Immuno-Oncology Study of Pancreatic Retrograde Venous Infusion of SD-101 Alone and With Checkpoint Blockade for Locally Advanced Pancreatic Ductal Adenocarcinoma
- Sponsor: TriSalus Life Sciences, Inc.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT05607953: https://clinicaltrials.gov/study/NCT05607953

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Nelitolimod](https://onco.cc/drugs/nelitolimod/)
- companies: [TriSalus Life Sciences](https://onco.cc/companies/trisalus-life-sciences/)

---
JSON: https://onco.cc/api/v1/entities/nct05607953.json